Organon &Amp; CO. (OGN) — SEC Filings

Overview

Organon &Amp; CO. (OGN) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K/A filed on Nov 10, 2025: Organon & Co. filed a 10-K/A on November 10, 2025, amending its Annual Report for the fiscal year ended December 31, 2024, due to an internal investigation into improper sales practices. The investigation, overseen by the Audit Committee, found that Organon asked two U.S. wholesalers to purchase exc

Sentiment Summary

Across 36 filings, the sentiment breakdown is: 4 bearish, 32 neutral. The dominant filing sentiment for Organon &Amp; CO. is neutral.

Filing Type Overview

Organon &Amp; CO. (OGN) has filed 1 4, 1 10-K/A, 6 10-Q, 19 8-K, 1 8-K/A, 2 DEF 14A, 2 10-K, 4 SC 13G/A with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (36)

• 4 Filing — 4 · Apr 2, 2026
• Organon Amends 10-K, Citing Improper Sales Practices and CEO Misconduct — 10-K/A · Nov 10, 2025 Risk: high
  Organon & Co. filed a 10-K/A on November 10, 2025, amending its Annual Report for the fiscal year ended December 31, 2024, due to an internal investigation into
• Organon's Net Income Halves Amid Rising Costs, Strategic Acquisitions — 10-Q · Nov 10, 2025 Risk: high
  Organon & Co. reported a significant decline in net income for the nine months ended September 30, 2025, falling to $392 million from $755 million in the prior
• 8-K Filing — 8-K · Nov 7, 2025
• Organon & Co. Files 8-K/A Amendment — 8-K/A · Oct 30, 2025 Risk: low
  Organon & Co. filed an amendment (8-K/A) on October 30, 2025, to a previous report. The amendment pertains to the departure of directors or certain officers, el
• Organon & Co. Files 8-K: Director Changes & Officer Appointments — 8-K · Oct 27, 2025 Risk: medium
  Organon & Co. filed an 8-K on October 27, 2025, reporting on the departure of directors, election of new directors, appointment of officers, and compensatory ar
• Organon Swings to Q2 Loss Amidst Revenue Dip, Litigation Woes — 10-Q · Aug 6, 2025 Risk: high
  Organon & Co. reported a net loss of $10 million for the second quarter of 2025, a significant decline from a net income of $150 million in the same period of 2
• Organon & Co. Files 8-K on Financials — 8-K · Aug 5, 2025 Risk: low
  Organon & Co. filed an 8-K report on August 5, 2025, detailing results of operations and financial condition. The filing also includes Regulation FD disclosures
• Organon & Co. Files 8-K on Director/Officer Changes — 8-K · Jun 12, 2025 Risk: low
  Organon & Co. filed an 8-K on June 12, 2025, reporting on events that occurred on June 10, 2025. The filing covers the departure and election of directors, appo
• Organon & Co. Files 8-K with Corporate Updates — 8-K · May 27, 2025 Risk: low
  Organon & Co. filed an 8-K on May 27, 2025, to report other events and financial statements. The filing details the company's corporate information, including i
• Organon & Co. Files Q1 2025 10-Q — 10-Q · May 2, 2025 Risk: low
  Organon & Co. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first quarter of 202
• Organon & Co. Files 8-K on Financials and Operations — 8-K · May 1, 2025 Risk: low
  Organon & Co. filed an 8-K on May 1, 2025, reporting on its results of operations and financial condition. The filing also includes disclosures related to Regul
• Organon & Co. Executive Compensation Revealed — DEF 14A · Apr 25, 2025 Risk: low
  Organon & Co. filed a DEF 14A on April 25, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information
• Organon & Co. Announces Board and Executive Compensation Changes — 8-K · Apr 15, 2025 Risk: medium
  Organon & Co. announced on April 15, 2025, changes in its board of directors and executive compensation arrangements. The filing details the departure of certai
• 10-K Filing — 10-K · Feb 28, 2025
• Organon & Co. Files 8-K on Financials — 8-K · Feb 13, 2025 Risk: low
  Organon & Co. filed an 8-K on February 13, 2025, reporting on its Results of Operations and Financial Condition, along with Regulation FD disclosures and financ
• Organon & Co. Reports Board Changes and Officer Compensation Updates — 8-K · Jan 21, 2025 Risk: low
  Organon & Co. announced on January 15, 2025, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the d
• Organon & Co. Files 8-K for Other Events — 8-K · Dec 23, 2024 Risk: low
  Organon & Co. filed an 8-K on December 23, 2024, reporting an event that occurred on December 20, 2024. The filing pertains to 'Other Events' and does not speci
• Organon & Co. Elects New Directors, Approves Executive Compensation — 8-K · Dec 6, 2024 Risk: low
  Organon & Co. announced on December 4, 2024, changes in its board of directors and executive compensation. Specifically, the company elected two new directors,
• Organon & Co. Files 8-K — 8-K · Nov 5, 2024 Risk: low
  Organon & Co. filed an 8-K on November 5, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain speci
• Organon & Co. Files Q3 2024 10-Q Report — 10-Q · Nov 1, 2024 Risk: low
  Organon & Co. filed its 10-Q for the period ending September 30, 2024. The filing covers the third quarter and the first nine months of the year. Key financial
• Organon & Co. Files 8-K on Financials — 8-K · Oct 31, 2024 Risk: low
  Organon & Co. filed an 8-K on October 31, 2024, reporting on its results of operations and financial condition. The filing also includes disclosures related to
• Organon & Co. Enters Material Definitive Agreement — 8-K · Sep 23, 2024 Risk: medium
  On September 17, 2024, Organon & Co. entered into a material definitive agreement. The filing does not provide specific details about the agreement, its counter
• Organon & Co. Files Q2 2024 10-Q Report — 10-Q · Aug 7, 2024 Risk: low
  Organon & Co. filed its 10-Q for the period ending June 30, 2024. The filing covers financial performance and operations for the second quarter and the first ha
• Organon & Co. Files 8-K on Financials — 8-K · Aug 6, 2024 Risk: low
  Organon & Co. filed an 8-K on August 6, 2024, to report on its results of operations and financial condition. The filing also includes information related to Re
• Organon & Co. Files 8-K on Shareholder Vote Matters — 8-K · Jun 6, 2024 Risk: low
  Organon & Co. filed an 8-K on June 6, 2024, reporting on matters submitted to a vote of security holders on June 4, 2024. The filing details the company's princ
• Organon & Co. Enters Material Definitive Agreement — 8-K · May 17, 2024 Risk: medium
  On May 17, 2024, Organon & Co. entered into a material definitive agreement. This filing also indicates the creation of a direct financial obligation or an obli
• Organon & Co. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 3, 2024 Risk: low
  Organon & Co. (OGN) filed a Quarterly Report (10-Q) with the SEC on May 3, 2024. Organon & Co. filed a 10-Q report for the period ending March 31, 2024. The fil
• Organon & Co. Files 8-K on Financials — 8-K · May 2, 2024 Risk: low
  Organon & Co. filed an 8-K on May 2, 2024, reporting on its results of operations and financial condition. The filing also includes information related to Regul
• Organon & Co. 2024 Shareholder Meeting & 2023 Dividend Payout — DEF 14A · Apr 25, 2024 Risk: low
  Organon & Co. is holding its 2024 Annual Meeting of Shareholders on June 4, 2024. The company reported that in 2023, it returned $294 million in cash dividends
• Organon & Co. Files 2023 Annual Report on Form 10-K — 10-K · Feb 26, 2024 Risk:
  Organon & Co. (OGN) filed a Annual Report (10-K) with the SEC on February 26, 2024. Organon & Co. reported its 2023 fiscal year results on Form 10-K, filed on F
• Organon Files 8-K on Financial Results and Disclosures — 8-K · Feb 15, 2024 Risk: low
  Organon & Co. filed an 8-K on February 15, 2024, to disclose its results of operations and financial condition. The filing also included Regulation FD disclosur
• SC 13G/A Filing — SC 13G/A · Feb 13, 2024
• Mawer Investment Management Divests Entire Organon Stake — SC 13G/A · Feb 5, 2024
  Mawer Investment Management Ltd., a Canadian investment firm, filed an amendment to its Schedule 13G on February 5, 2024, indicating that as of December 31, 202
• State Street Corp. Maintains Passive Stake in Organon & Co. — SC 13G/A · Jan 25, 2024
  State Street Corporation, a major financial institution, filed an amended SC 13G/A on January 25, 2024, indicating its ownership of Organon & Co. common stock a
• BlackRock Amends Organon Stake, Maintains Passive Position — SC 13G/A · Jan 23, 2024
  BlackRock Inc. filed an amended SC 13G/A on January 23, 2024, disclosing its ownership in Organon & Co. as of December 31, 2023. This filing, Amendment No. 3, i

Risk Profile

Risk Assessment: Of OGN's 28 recent filings, 3 were flagged as high-risk, 4 as medium-risk, and 21 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Organon &Amp; CO.'s most recent 10-Q filing (Nov 10, 2025):

• Revenue: $4,709M
• Net Income: $392M
• EPS: $1.50
• Debt-to-Equity: 14.8
• Cash Position: $672M
• Operating Margin: 27.1%
• Total Assets: $13,552M
• Total Debt: $8,828M

Key Executives

• Kevin Ali
• Joseph Morrissey
• Carrie S. Cox
• Robert Essner
• Chief Executive Officer
• Sarah E. Emond
• David M. Stack
• Michael McInerney

Industry Context

The pharmaceutical industry is highly competitive, characterized by significant R&D investment, patent cliffs, and increasing regulatory oversight. Companies like Organon focus on specific therapeutic areas, with women's health and contraceptives being key segments. The market is sensitive to product innovation, pricing pressures, and the impact of generic competition following patent expirations.

Top Tags

Pharmaceuticals (4) · corporate-governance (4) · 10-Q (4) · disclosure (4) · sec-filing (4) · amendment (3) · financial-reporting (3) · quarterly-report (3) · pharmaceuticals (3) · executive-compensation (3)

Key Numbers

• Market Value of Non-Affiliate Common Equity: $5.3B — As of June 30, 2024, reflecting the company's size before the scandal broke.
• Incremental Nexplanon Sales as % of Consolidated Revenue: <1% — For fiscal years ended December 31, 2022 and 2024, indicating the relative financial impact of the improper sales practices.
• Incremental Nexplanon Sales as % of Quarterly Consolidated Revenue: <2% — For relevant quarterly periods, highlighting the localized impact of the sales practices.
• Common Stock Shares Outstanding: 257.95M — As of February 25, 2025, providing context for market capitalization.
• Net income for nine months ended Sept 30, 2025: $392M — decreased from $755M in 2024, a 48.1% decline
• Revenues for three months ended Sept 30, 2025: $1,602M — increased from $1,582M in 2024
• Revenues for nine months ended Sept 30, 2025: $4,709M — decreased from $4,811M in 2024
• Restructuring costs for nine months ended Sept 30, 2025: $88M — increased from $23M in 2024
• Upfront payment for Tofidence rights: $51M — paid to Biogen in July 2025
• Cost of sales for three months ended Sept 30, 2025: $745M — increased from $659M in 2024
• Cost of sales for nine months ended Sept 30, 2025: $2,137M — increased from $1,992M in 2024
• Research and development for nine months ended Sept 30, 2025: $275M — decreased from $339M in 2024
• Common stock outstanding as of Nov 3, 2025: 259,982,912 — increased from 257,799,000 as of Dec 31, 2024
• Total Stockholders' Equity as of Sept 30, 2025: $906M — increased from $472M as of Dec 31, 2024
• Net Loss: $10M — Q2 2025, a significant decline from $150M net income in Q2 2024

Related Companies

BIIB · ABBV · AMGN · LLY

Frequently Asked Questions